TD Cowen Initiates Coverage On Astria Therapeutics with Buy Rating, Announces Price Target of $35
Portfolio Pulse from Benzinga Newsdesk
TD Cowen has initiated coverage on Astria Therapeutics (NASDAQ:ATXS) with a Buy rating and set a price target of $35.
July 29, 2024 | 11:00 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TD Cowen has initiated coverage on Astria Therapeutics with a Buy rating and set a price target of $35.
The initiation of coverage with a Buy rating and a specific price target of $35 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100